Завод ДИОД logo
Завод ДИОД DIOD

Завод ДИОД Income Statement 2007-2025 | DIOD

Annual Income Statement Завод ДИОД

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

Revenue

549 M 561 M 602 M 517 M 658 M 774 M 825 M 886 M 964 M 1.28 B 1.14 B 1.15 B 1.55 B 1.55 B 1.56 B 1.73 B 1.62 B

Cost Of Revenue

255 M 242 M 245 M 192 M 300 M 329 M 411 M 485 M 316 M 583 M 400 M 460 M 711 M 752 M 726 M 674 M 677 M

Gross Profit

294 M 319 M 357 M 325 M 358 M 446 M 414 M 401 M 649 M 700 M 737 M 691 M 839 M 796 M 833 M 1.06 B 947 M

Gross Profit Ratio

0.54 0.57 0.59 0.63 0.54 0.58 0.5 0.45 0.67 0.55 0.65 0.6 0.54 0.51 0.53 0.61 0.58

General and Administrative Expenses

162 M 29.8 M 23.2 M 19.7 M 27.3 M 136 M 37.4 M 50.7 M 28.2 M 23.8 M 164 M 27.4 M 156 M 150 M 160 M 154 M -

Selling And Marketing Expenses

122 M 68.6 M 96.7 M 97.5 M 125 M 195 M 262 M 122 M 336 M 286 M 390 M 286 M 383 M 332 M 369 M 516 M -

Selling General And Administrative Expenses

293 M 98.3 M 120 M 117 M 153 M 371 M 300 M 173 M 364 M 310 M 553 M 314 M 539 M 482 M 529 M 670 M 538 M

Other Expenses

-690 K 175 M 141 M 132 M 134 M 18.2 M -37.3 M 4.17 M -24.6 M 193 M -207 M -11 M -52.5 M -46.8 M -236 M -88.5 M 57.8 M

Operating Expenses

292 M 274 M 261 M 249 M 286 M 389 M 467 M 362 M 572 M 517 M 554 M 533 M 549 M 493 M 310 M 599 M 614 M

Cost And Expenses

547 M 516 M 507 M 441 M 586 M 718 M 879 M 847 M 888 M 1.1 B 954 M 992 M 1.26 B 1.25 B 1.04 B 1.27 B -1.29 B

Interest Expense

- 37 K 19 K 576 K 3.52 M - 23.5 M 37.2 M 112 M 94.4 M 99.8 M 97.9 M 89.6 M 93.6 M 116 M 44.1 M 2.02 M

Depreciation And Amortization

20.6 M 5.24 M 15.9 M 18.5 M 18.1 M 29.9 M 26.5 M 28.6 M 6.54 M 9.73 M -206 M 4.6 M -51.1 M -44 M 2.2 M -4.54 M 20.5 M

EBITDA

22.4 M 65.2 M 131 M 77.2 M 109 M 90.4 M 35.7 M -66.2 M 12.6 M 185 M 6.28 M 151 M 251 M 259 M 570 M 452 M 357 M

EBITDA Ratio

0.04 0.12 0.2 0.16 0.16 0.12 -0.08 -0.01 -0.17 0.14 -0.02 0.13 0.15 0.17 0.34 0.26 0.22

Operating Income

1.82 M 45.2 M 107 M 73.2 M 99.2 M 56.4 M -46.5 M 49.5 M 91.9 M 184 M 183 M 163 M 291 M 303 M 523 M 457 M 333 M

Operating Income Ratio

0.0 0.08 0.18 0.14 0.15 0.07 -0.06 0.06 0.1 0.14 0.16 0.14 0.19 0.2 0.34 0.26 0.21

Income Before Tax

13.4 M 60 M 115 M 57.1 M 80.8 M 46.7 M -26.9 M -134 M -106 M 81.1 M -137 M 25.1 M 150 M 165 M 410 M 408 M 335 M

Income Before Tax Ratio

0.02 0.11 0.19 0.11 0.12 60.4 -0.03 -0.15 -0.11 0.06 -0.12 0.02 0.1 0.11 0.26 0.24 0.21

Income Tax Expense

4.98 M 17.6 M 26.1 M 22.3 M 15.5 M 36.5 M -10.6 M 6.88 M 13.3 M 22.8 M 20.2 M 17.2 M 37.8 M 35.4 M 45.8 M 106 M 101 M

Net Income Ratio

0.02 0.07 0.15 0.07 0.1 0.01 -0.03 -0.16 -0.12 0.04 -0.14 0.01 0.08 0.11 0.24 0.17 0.14

Earnings Per Share, EPS

0.09 0.44 0.99 0.38 0.7 0.12 -0.29 -1.54 -1.31 0.63 -1.71 0.15 1.4 1.78 4.08 33.1 K 50 K

EPS Diluted

0.09 0.44 0.99 0.38 0.7 0.12 -0.29 -1.54 -1.31 0.63 -1.71 0.15 1.4 1.78 4.08 33.1 K -

Weighted Average Shares Outstanding

91.5 M 91.5 M 91.5 M 98 M 92 M 91.5 M 90.5 M 91.5 M 91.5 M 91.5 M 91.5 M 91.5 M 91.5 M 91.5 M 91.5 M 9.15 K 9.15 K

All numbers in RUB currency

Quarterly Income Statement Завод ДИОД

2023-Q2 2022-Q4 2022-Q2 2021-Q4 2021-Q2 2020-Q4 2020-Q2 2019-Q4 2019-Q2 2018-Q4 2018-Q2 2017-Q4 2017-Q2 2016-Q4 2016-Q2 2015-Q4 2015-Q2 2014-Q4 2014-Q2 2013-Q4 2013-Q2 2011-Q4 2011-Q2 2010-Q4 2010-Q2 2009-Q4 2009-Q2 2008-Q4 2008-Q2

Revenue

274 M 260 K 301 M 294 M 309 M 299 M 218 M 322 M 336 M 385 M 389 M 370 M 455 M 413 M 473 M 549 M 415 M 642 M 642 M 638 M 249 M 775 M 775 M 774 M 774 M 779 M 779 M 865 M 865 M

Cost Of Revenue

127 M 118 K 131 M 138 M 113 M 114 M 78.1 M 115 M 189 M 171 M 157 M 193 M 218 M 228 M 258 M 229 M 138 M 291 M 291 M 233 M 83.6 M 356 M 356 M 376 M 376 M 363 M 363 M 337 M 337 M

Gross Profit

147 M 142 K 171 M 156 M 195 M 185 M 140 M 206 M 147 M 214 M 232 M 177 M 237 M 185 M 215 M 320 M 278 M 350 M 350 M 405 M 166 M 420 M 420 M 398 M 398 M 417 M 417 M 528 M 528 M

Gross Profit Ratio

0.536 0.547 0.566 0.53 0.632 0.618 0.642 0.642 0.437 0.555 0.596 0.502 0.52 0.448 0.455 0.584 0.668 0.546 0.546 0.635 0.665 0.541 0.541 0.514 0.514 0.534 0.534 0.611 0.611

General and Administrative Expenses

81 M 70.6 K 43.8 K - - 63 M 57.3 M - - 64.6 M 71.5 M -35.6 M 73 M 90.6 M 92.7 M 85.5 M 68.3 M 11.9 M 11.9 M 91.3 M 31.6 M 78.2 M 78.2 M 75 M 75 M 79.9 M 79.9 M 76.9 M 76.9 M

Selling And Marketing Expenses

61.1 M 33.1 K 32.6 K - - 60.8 M 67.8 M - - 92.7 M 103 M 149 M 113 M 96.8 M 55.2 M 173 M 198 M 143 M 143 M 238 M 68.8 M 192 M 192 M 166 M 166 M 184 M 184 M 258 M 258 M

Selling General And Administrative Expenses

146 M 111 K 153 M 140 M 121 M 127 M 127 M 174 M 124 M 190 M 181 M 108 M 192 M 189 M 167 M 406 M 283 M 155 M 155 M 344 M 106 M 270 M 270 M 241 M 241 M 264 M 264 M 335 M 335 M

Other Expenses

-345 K - 488 K 826 K 662 K 18.6 M 4.4 M -8.65 M 4.92 M 18.2 M - -58.1 M 20.8 M 6.22 M -12.1 M -177 M -9.03 M 96.5 M 96.5 M -31.2 M 13.9 M -26.2 M -26.2 M -23.4 M -23.4 M -118 M -118 M -44.3 M -44.3 M

Operating Expenses

146 M 115 K 152 M 139 M 120 M 146 M 131 M 183 M 119 M 208 M 181 M 255 M 213 M 196 M 155 M 230 M 276 M 258 M 258 M 313 M 121 M 274 M 274 M 247 M 247 M 155 M 155 M 300 M 300 M

Cost And Expenses

273 M 233 K 283 M 277 M 234 M 260 M 209 M 298 M 308 M 379 M 339 M 448 M 431 M 423 M 413 M 458 M 414 M 550 M 550 M 546 M 204 M 630 M 630 M 623 M 623 M 518 M 518 M 636 M 636 M

Interest Expense

- - - 569 K 424 K - - 424 M 2.39 B - - 23.5 M - - - - - 47.2 M 47.2 M - - 44.8 M 44.8 M 46.8 M 46.8 M 57.9 M 57.9 M 22 M 22 M

Depreciation And Amortization

10.3 M 6.4 K 10.4 M 6.89 M 9.01 M 10.5 M 9.9 M 1.92 M 16.2 M 8.29 M 21.6 M 11.2 M 15.3 M 17.9 M 10.7 M 28.9 M 31.8 M 4.87 M 4.87 M 18.6 M 8.39 M -25.6 M -25.6 M -22 M -22 M 1.1 M 1.1 M -2.27 M -2.27 M

EBITDA

11.2 M 34.4 K 28.8 M 23.3 M 89.1 M 65.9 M 18.6 M 25.3 M 44 M 18.2 M 72.1 M -24.3 M 60 M 13.4 M 58.8 M -71.6 M 8.19 M 92.6 M 92.6 M 108 M 53.6 M 126 M 126 M 129 M 129 M 285 M 285 M 226 M 226 M

EBITDA Ratio

0.041 0.133 0.096 0.079 0.271 0.221 0.085 0.079 0.131 0.047 0.185 -0.079 0.132 0.032 0.124 -0.13 0.02 0.144 0.144 0.169 0.215 0.162 0.162 0.167 0.167 0.366 0.366 0.262 0.262

Operating Income

909 K 28 K 18.4 M 16.4 M 74.7 M 39.1 M 8.82 M 23.3 M 27.8 M 5.91 M 50.5 M -70.4 M 23.9 M -10.7 M 60.2 M 90.6 M 1.31 M 91.8 M 91.8 M 92.4 M 45.3 M 145 M 145 M 151 M 151 M 262 M 262 M 228 M 228 M

Operating Income Ratio

0.003 0.108 0.061 0.056 0.242 0.131 0.04 0.073 0.083 0.015 0.13 -0.056 0.053 -0.026 0.127 0.165 0.003 0.143 0.143 0.145 0.182 0.188 0.188 0.195 0.195 0.336 0.336 0.264 0.264

Income Before Tax

6.7 M 32.8 K 27.1 M 34.9 M 79.6 M 42 M 15.1 M 28.6 M 52.2 M 17.4 M 29.4 M -65 M 38.2 M -16 M -118 M -32.5 M -73.6 M 40.6 M 40.6 M 21.4 M -79.1 M 75 M 75 M 82.5 M 82.5 M 205 M 205 M 204 M 204 M

Income Before Tax Ratio

0.024 0.126 0.09 0.119 0.258 0.141 0.069 0.089 0.155 45.1 75.5 -0.033 0.084 -0.039 -0.25 -0.059 -0.177 0.063 0.063 0.034 -0.317 0.097 0.097 0.107 0.107 0.263 0.263 0.236 0.236

Income Tax Expense

2.49 M 7.44 K 10.2 M 8.79 M 17.3 M 15.5 M 6.78 M 20.6 M -5.06 M 24.7 M 11.8 M -14.3 M 3.68 M 19.1 M -24.5 M 46.5 M -66.4 M 11.4 M 11.4 M 10.5 M 4.87 M 18.9 M 18.9 M 17.7 M 17.7 M 22.9 M 22.9 M 52.9 M 52.9 M

Net Income Ratio

0.015 0.103 0.052 0.097 0.202 0.098 0.037 0.023 0.169 -0.024 0.052 -0.032 0.075 -0.083 -0.225 -0.144 -0.098 0.045 0.045 0.016 -0.335 0.082 0.082 0.105 0.105 0.24 0.24 0.175 0.175

Earnings Per Share, EPS

0.046 0.0 0.17 0.31 0.68 0.32 0.09 0.083 0.63 -0.1 0.22 -0.67 0.38 -0.38 -1.16 -0.86 -0.44 0.315 0.315 0.113 -0.91 0.7 0.7 0.89 0.89 2.04 2.04 16.5 K 16.5 K

EPS Diluted

0.046 0.0 0.17 0.31 0.68 0.32 0.09 0.083 0.63 -0.1 0.22 -0.67 0.38 -0.38 -1.16 -0.86 -0.44 0.315 0.315 0.113 -0.91 0.7 0.7 0.89 0.89 2.04 2.04 16.5 K 16.5 K

Weighted Average Shares Outstanding

91.5 M 91.4 M 91.5 M 91.5 M 91.5 M 93.6 M 89.4 M 91.5 M 90.5 M 92.5 M 90.5 M 90.5 M 91.5 M 91.5 M 91.5 M 91.5 M 91.5 M 91.5 M 91.5 M 91.5 M 91.5 M 91.5 M 91.5 M 91.5 M 91.5 M 91.5 M 91.5 M 9.15 K 9.15 K

All numbers in RUB currency

The income statement is one of the three key financial reports of a company Завод ДИОД (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
AbbVie AbbVie
ABBV
$ 223.01 -0.99 % $ 395 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.68 1.85 % $ 777 M canadaCanada
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.38 3.21 % $ 261 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 212.3 5.5 % $ 5 B danmarkDanmark
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
BioVie BioVie
BIVI
$ 1.54 -2.53 % $ 2.28 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 1.33 -1.48 % $ 7.25 M chinaChina
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.4 1.49 % $ 8.18 B australiaAustralia
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
$ 90.34 -1.28 % $ 96.9 B britainBritain
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 25.76 0.19 % $ 1.25 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 9.53 -1.19 % $ 140 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.33 2.3 % $ 14.6 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Axon Enterprise Axon Enterprise
AXON
$ 586.28 3.15 % $ 44.4 B usaUSA
Biogen Biogen
BIIB
$ 173.03 -2.55 % $ 25.2 B usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 0.29 -5.01 % $ 631 M israelIsrael
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
$ 12.91 0.78 % $ 531 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 95.9 0.17 % $ 27.2 B germanyGermany
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 11.55 8.86 % $ 747 M usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
- - $ 40.5 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 15.32 5.73 % $ 1.01 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Cerus Corporation Cerus Corporation
CERS
$ 2.14 13.23 % $ 395 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 9.15 -0.44 % $ 1.47 B britainBritain
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 3.81 -5.35 % $ 46.6 M usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 51.05 -0.32 % $ 103 B usaUSA
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 5.5 0.46 % $ 118 M usaUSA
ADiTx Therapeutics ADiTx Therapeutics
ADTX
$ 2.36 -7.29 % $ 31.1 K usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 2.1 -4.34 % $ 5.32 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.42 6.77 % $ 134 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 3.22 -2.72 % $ 908 M israelIsrael
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 28.33 0.5 % $ 1.82 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Baudax Bio Baudax Bio
BXRX
- 0.59 % $ 63 K usaUSA